04/17/2025
5:08 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/16/2025
8:34 AM | Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/06/2025
5:54 PM | Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/06/2025
5:55 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/06/2025
5:55 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/28/2025
3:02 PM | Ligand Pharmaceuticals (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
02/27/2025
6:06 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/19/2025
7:44 PM | Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/19/2025
7:37 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/19/2025
7:38 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/14/2025
11:36 AM | JANUS HENDERSON GROUP PLC (Filed by)
Ligand Pharmaceuticals (Subject)
| Form SCHEDULE 13G/A | |
Get the Latest News and Ratings for LGND and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. |
12/26/2024
7:32 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/23/2024
7:19 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/06/2024
6:55 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/02/2024
7:05 PM | LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/27/2024
3:44 PM | LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/14/2024
2:19 PM | JANUS HENDERSON GROUP PLC (Filed by)
Ligand Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/08/2024
4:34 PM | GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
Ligand Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/07/2024
6:11 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/01/2024
3:07 PM | Ligand Pharmaceuticals (Subject)
MACQUARIE GROUP LTD (Filed by)
| Form SC 13G/A | |
09/25/2024
7:54 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/24/2024
6:41 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/24/2024
6:41 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/23/2024
4:27 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/23/2024
4:30 PM | Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/20/2024
5:12 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/20/2024
4:39 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/19/2024
4:50 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/18/2024
6:55 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/30/2024
8:00 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/30/2024
7:56 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/28/2024
3:39 PM | Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/26/2024
7:15 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/22/2024
5:05 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/13/2024
4:21 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/09/2024
4:52 PM | Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/09/2024
4:16 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/07/2024
3:30 PM | Ligand Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
07/17/2024
4:10 PM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/10/2024
3:02 PM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/08/2024
6:38 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
Altucher: Turn $900 into $108,000 in just 12 months? (Ad) We are entering the final Trump Bump of our lives.
But the biggest returns will not be in the stock market. If I’m right about this (like I was before) a modest $900 investment… |
07/02/2024
6:44 PM | Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/02/2024
6:45 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/02/2024
6:45 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/02/2024
6:45 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/27/2024
8:10 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/25/2024
6:45 PM | Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
8:25 PM | Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
8:26 PM | Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
8:26 PM | Haas Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
8:26 PM | KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
8:27 PM | LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
8:27 PM | Ligand Pharmaceuticals (Issuer)
Zimmermann Martine (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
4:14 PM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/17/2024
6:59 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/17/2024
7:00 PM | Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/17/2024
4:45 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/16/2024
4:39 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/15/2024
6:34 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/15/2024
5:01 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/15/2024
1:45 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144/A | |
05/14/2024
6:42 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/13/2024
5:14 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/13/2024
4:32 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2024
5:03 PM | Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/09/2024
5:06 PM | Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/09/2024
3:11 PM | Ligand Pharmaceuticals (Filer)
| Form DEFA14A | |
05/07/2024
6:36 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
Buy LGND Stock Free LGND Stock Alerts